Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?

Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and$22.44 billion in revenues as the company reports before market hours.The stock is down 8.88% over the past year, up 2.79% YTD.Johnson & Johnson's Spravato Wins FDA Nod Ahead Of EarningsJohnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressa ...